Skip to content

Released May 9, 2022, before the open

10-Q filed May 9, 2022, 39 days after period end · 0001628280-22-013333

Q1 2022 · 10-Q
Revenue$3.92M+1,270.6% vs Q1 2021+449.8% vs Q4 2021
Net Income-$26.91MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.65N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$27,804,000N/M
Operating Cash Flow$271,534,000N/M
Free Cash Flowderived$271,287,000N/M
Margins · derived
Operating margin-709.3%+7378.1 pt vs Q1 2021
Net margin-686.6%+7350.5 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020
Revenue$3.92M$286.00K$0.00
Net Income-$26.91M-$22.99M-$13.95M
EPS Diluted-$0.65-$0.62-$2.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR